A 46-year-old womanwith incidentally discovered thyrotropin (TSH)-producing pituitary adenoma showed endocrine data which was consistent with TSH-producing pituitary tumor. However,she showed only slight hyperthyroidism and the oversecretion and autonomoussecretion of TSH from the tumor seemed to be limited from the results of several endocrine examinations. Immunohistochemical examination revealed that not only TSH-p and TSH-a but also prolactin and growth hormone synthesizing cells were present in the tumor tissue. Pituitary-transcription activator 1 (Pit-1) immunoreactivity was also detected in the adenoma cell nuclei. It was conceivable that the presented TSH-producing adenoma clinically located close to the nonfunctioning adenoma and Pit-1 may have played an important role in the multidirectional differentiation or development of this tumor.
Introduction

Thyrotropin
(TSH)-producing pituitary adenoma is relatively rare and constitutes about 1% of pituitary adenoma (1). The patients usually show symptoms ofhyperthyroidism (sweating, palpitation, weight loss, and diffuse goitor), and are often misdiagnosed and treated as Graves' disease (2-4). The tumor is usually huge when discovered. However, since the method of measuring TSH has recently become very sensitive, pituitary tumor can be suspected when the serum TSH level is inappropriately high for the serum thyroid hormone levels even if it is not absolutely high (4). On the other hand, magnetic resonance imaging (MRI) examination has become popular and nowthe possibility of incidentally discovering pituitary tumor has increased. In adult autopsies the incidence of pituitary microadenoma has varied between 6 and 23% (1). In one series, the incidence of pituitary tumor with state-of-the-art MRI and gadolinium enhancement has been reported to be 10% (5). Thus, it is likely that pituitary incidentaloma is not rare. In the present paper we report a patient with incidentally discovered TSH-producing pituitary adenoma who showed only slight symptoms of hyperthyroidism and present results of the immunohistochemistry for several pituitary hormones and pituitarytranscription activator 1 (Pit-1) (6) in the resected tumor.
Materials and Methods
Hormone measurement
All hormone levels in serum or plasma were measured by commercially available radioimmunoassay kits except for the measurement of serum TSH-oc subunit (TSH-a) level. Serum free triiodothyronine (fT3) and free thyroxine (fT4) levels were measured by AMERLEX-M free T3 kitá" and AMERLEX-M free T4 kitá" (Amersham International pic, Bucks, UK). Serum TSH level was measured by TSH^RIA BEADS IIá" (Dainabot, Tokyo, Japan). Plasma growth hormone (GH), luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels were measured with GH kit Daiichiá", SPAK-S LH kitá" and SPAK-S FSH kitá" (Daiichi Radioisotope, Tokyo, Japan), respectively. Plasma prolactin (PRL) and adrenocorticotropin (ACTH) levels were measured using SPAK-S PRLá" (Daiichi Radioisotope) and ALLEGRO HS-ACTHá" (Nichols Institute, Sari Juan Capistrano, CA, USA), respectively, which are immunoradiometric assay systems. Reference ranges of serum orplasma hormone levels were as follows; fT3, 4.65-9.00 pmol//; fT4, 10.9-27.7 pmol//; TSH, 0.6-5.1 mU//; TSH-a, 29.3-353. 1 pmol//; PRL, 1.4-14.6 jag//; GH, 0.66-3.68 jig//, LH in post menopausal phase, 8.7-38.0 IU//; FSH in post menopausal phase, 26.2-1 13.3 IU//; ACTH, 1.98-1 1.5 pmol//. (Fig. 1) . No visual disturbance was seen on ophthalmological examination. On admission, the skin was moist and Achilles' tendon reflex was slightly accelerated, but no goitor, finger tremor or weight loss was found. Pulse rate was 84/min and blood pressure was 132/84 mmHg. On laboratory examination, blood count and biochemical data were unremarkable. The plasma glucose levels after oral administration of 75g glucose showed oxyhyperglycemic pattern, increasing from 5.16 mmol// to a peak of 1 1.21 mmol/ / at 30 minutes and returning to 6.72 mmol// at 120 minutes. Serum fT3 and fT4 levels were slightly high or in the upper limit of the reference range, being 10.1-10.7 pmol// and 27.4-27.7 pmol//, respectively. Serum TSH level was, however, within the normal range (2.3-3.7 mU//), which was an inappropriately high level for serum fT3 and fT4 levels. Serum SHBG level was slightly high, at 120 nmol//. No diurnal rhythm was shown in serum TSH levels, being 2.2 mU// at 0600, 2.0 at 0900, 2.0 at 2100, and 2.1 at 2300. Serum TSH-a level was high, at 642 to 925 pmol//. The molar ratio of TSH-a to TSH in serum was high, being 24.5. Basal metabolic rate was normal, being 8% (reference range, -10 -10%) and 123I uptake of thyroid gland for 24 hours was 20%. TRAb and TSBAb were negative, being 4.2% and 7.5%, respectively. Both ofanti-T3 and anti-T4 Immunohistochemically, anti-TSH antibodies stained the majority of the tumor cells strongly (Fig. 3a) . Anti-TSH-a antibodies (Fig. 4a) and anti-TSH-p antibodies (Fig. 4b ) also stained these cells.
Furthermore, tumor cells were stained with anti-PRL antibodies (Fig. 3a) . Anti-GH antibodies stained the same cells faintly (Fig. 3b) cell nuclei of the adenoma cells (Fig. 4c) .
Discussion
Ambiguous symptoms of hyperthyroidism in this patient were supported by normal findings of 123I uptake of thyroid gland and the basal metabolic rate. The oxyhyperglycemic pattern of plasma glucose level in glucose tolerance test and the slightly increased serum SHBG level were compatible with hyperthyroidism.The basal serum levels of fT3, fT4, and TSH were consistent with inappropriate secretion of TSH, which includes TSH-producing tumor and selective pituitary resistance to thyroid hormone action (4). The high TSH-a levels and high TSH-a to TSH molar ratios in this patient virtually excluded the diagnosis of the latter (4, 9). These results indicate that the pituitary tumor of this patient overproduces TSH, although hyperactivity and autonomity of the tumor is likely limited. The pathogenesis of hyperthyroidism in the setting of normal TSH levels in this patient is poorly understood, but biologic activity of TSH molecules may be increased as previously postulated (10) and reported (3).
T he response of serum TSH levels to TRH is variable in patients with TSH-producing pituitary adenoma; about 60% of reported patients showed no response, which is similar to the present patient (4) and the absence of TRH receptor in such tumors wasreported ( 1 1). Disappearance of diurnal rhythm of serum TSH level was also consisted with the previously reported patients with TSH-producing tumor (3, 12). The decreasing effect of a single administration of bromocriptine on serum TSH and TSH-a levels in this patient may be rather a minor (13), because a majority of the previous patients with TSH-producing tumor did not show a significant fall in serum TSH level (14). However, the reduction of serum TSH level by an acute challenge of somatostatin analog (octreotide acetate) in this patient was consistent with the previous reports (12, 15).
T he serum TSH level has been reported to be partially suppressed by daily administration ofT3 in 25% of40 reviewed patients with TSH-producing tumor (4), which was also seen in this patient, and was not suppressed in the remaining patients. It has been reported that the synthesis of both mRNAof alpha and beta subunits of TSH in pituitary cells are suppressed by thyroid hormone.The degree of suppression is greater for TSHp than for TSH-a (16). However, the increase of the ratio of TSH-a to TSH during T3 suppression test in this patient indicated that the degree of suppression with T3 was greater for TSH than for TSH-a. Accordingly, TSH-p seemed to be conversely more suppressed than TSH-a in this patient. We can postulate one possibility that the gene expression only in TSHa-producing cells might have been unsuppressed by T3 administration. In the immunohistochemical examination, however, we could not demonstrate clearly whether tumor cells producing TSH-a alone were present. As another possibility, the asubunit of LH and FSH may have affected this phenomenon, because they were overproduced due to the postmenopausal state of this patient and were not suppressed by T3 administration.
S imultaneous overproduction of PRL and/or GH and/or LH and FSH in TSH-producing pituitary adenoma has been reported (3, (17) (18) (19) 
